ImmuPharma (IMM)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | n/a |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 3.46 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | +19.8% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, ImmuPharma PLC revenues decreased from L17K to L0K. Net loss increased 15% to L3.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Administrative expenses increase of 14% to L2.6M (expense), Finance income decrease of 61% to L88K (income), Finance costs increase from L1K to L4K (expense). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 1 | 0 | 0 | 1 | 1 |
ImmuPharma plc is a drug discovery and development company. The Company focuses on developing drugs, based on peptide therapeutics, to treat medical conditions such as autoimmune diseases. The Company has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). As of December 31, 2011, the Company had five drug candidates, such as Lupuzor to treat lupus; IPP-204106, to treat cancer; IPP-201007 to treat inflammation/allergic conditions, such as asthma and rheumatoid arthritis; IPP-102199 to treat moderate to severe pain, such as cancer and postoperative pain, and IPP-203101to treat severe resistant hospital-acquired infections, such as methicillin-resistant staphylococcus aureus (MRSA). As of March 27, 2012, Lupuzor received approval from the Food and Drug Administration to start a Phase III trial.
Directors: Richard Warr (Chmn.) , Robert Zimmer (Pres.) , Dimitri Dimitriou (CEO) , Tracy Weimar (VP-Fin.) ,
No. of Employees: 7 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 81,532,463 |
| Free Float | 47.8m (58.7%) |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | 50 Broadway Westminster, LONDON, SW1H 0RG, United Kingdom |
| Web | http://www.immupharma.com/ |
| Phone | +44 20 71524080 |
| Contact | Tracy Weimar (Secy.) |
| Registrar | Computershare Investor Services PLC (Bristol) |
| Auditors | Nexia Smith & Williamson |
| 22nd Apr | Posting of Annual Report and AGM Notice |
| 9th Apr | Preliminary Results |
| 28th Feb | ImmuPharma Commences Trading on Stuttgart Exchange |
| 28th Jan | Director/PDMR Shareholding - Replacement |
| 28th Jan | Director/PDMR Shareholding |
| 28th Jan | CNRS Confirms Lupuzors (TM) Effectiveness |
Recent ↓
